To investigate the effect of menatetrenone on bone turnover in postmenopausal patients with osteoporosis. One month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin. Moderate increases of bone resorption and formation markers were observed after 6 months. These changes may contribute to fracture prevention in patients with osteoporosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
131
Unnamed facility
Kumagaya-shi, Saitama, Japan
Unnamed facility
Hachioji-shi, Tokyo, Japan
Unnamed facility
Setagaya-Ku, Tokyo, Japan
Unnamed facility
Nishiyatsushiro-Gun, Yamanashi, Japan
Gamma-carboxylation
Bone turnover marker
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.